Across TCGA pan-cancer cohorts, SAP30L Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SAP30L data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SAP30L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SAP30L expression acts as an unfavorable survival marker.
HNSC and CHOL are the cancer types where SAP30L Mutation most reproducibly stratifies survival.